At a time when fresh COVID-19 infections are declining across many states in the country, mucormycosis, popularly known as black fungus, has emerged as a major challenge for India. Over 11,717 cases of the rare fungal infection have been reported in the country so far. Of it, the maximum number of cases has been registered in Gujarat followed by Maharashtra and Andhra Pradesh.
As per a tally shared by Union chemicals and fertilisers minister DV Sadananda Gowda, Gujarat has reported 2,859 cases of black fungus till May 25. Maharashtra reported 2,770 cases followed by 768 cases in Andhra Pradesh. Madhya Pradesh has reported 752 cases followed by 481 cases in Karnataka and 436 cases in Haryana.
Allocation of medicines for mucormycosis
The Union government said 23,680 vials of Amphotericin-B, which is used in the treatment of mucormycosis, were supplied to states on May 21. Additionally, 19,420 vials of the drug were supplied to states on May 24.
Gowda in a tweet revealed that 29,250 vials of the drug were allocated to states today. The highest allocation has been made for Gujarat, followed by Maharashtra. Notably, West Bengal and the north-eastern states have not reported any cases of the deadly fungal infection.
The minister tweeted, “Additional 29,250 vials of #Amphotericin- B drug, used in the treatment of #Mucormycosis, have been allocated to all the States/UTs today. The allocation has been made based on the number of patients under treatment which is 11,717 across the country.”
— Sadananda Gowda (@DVSadanandGowda) May 26, 2021
Who are at risk
People get infected with mucormycosis by coming in contact with the fungal spores in the environment. It can also develop on the skin after the fungus enters the skin through a cut, scrape, burn, or other types of skin trauma.
This disease has been detected among patients who suffered from COVID-19 and are recovering or those who are still infected with the deadly virus.
Experts believe that the treatment of COVID-19 patients involves the intake of drugs like dexamethasone, which suppresses the immune system response. Due to this, COVID- 19 patients face a renewed risk of failing in the battle against attacks mounted by an organism such as mucormycetes.
To read the latest news in Gujarati click here